27th Oct 2015 07:54
LONDON (Alliance News) - Specialty pharmaceutical company Clinigen Group PLC on Tuesday said its key programmes remain on track and said it expects further progress in the coming year.
In a statement to be given at Clinigen's annual general meeting, Chairman Peter Allen and Chief Executive Peter George said all of the company's specialty pharmaceutical assets, including Cardioxane, Savene and Ethyol, are progressing on track.
"Clinigen's strong financial performance demonstrates its strengthened international position in growing markets. The group is on track in advancing its underlying philosophy of getting the right drug to the right patient at the right time, regardless of where they are in the world," the pair said.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L